Head-to-head evidence
Dorzagliatin vs GK1-399 (formerly TTP399)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
Dorzagliatin · Huatangning
Developed by Hua Medicine
NCT04531631 · Phase 2 · completed
The study used randomized, triple-blind, placebo-controlled crossover treatment, but enrolled only 18 participants and measured a mechanistic insulin-response biomarker rather than a clinical diabetes outcome. Because the registry provides no primary-endpoint results, it is not possible to determine whether the comparison met its prespecified endpoint.
Next expected readout: March 2029 · NCT07786571 (registry estimate)
GK1-399 (formerly TTP399)
Developed by vTv Therapeutics
NCT01474083 · Phase 1/2 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 248 participants across three GK1-399 dose groups and a placebo group. Its primary endpoint was a pharmacokinetic measure, a surrogate rather than a clinical outcome, and no primary endpoint results are posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dorzagliatin's landscape · GK1-399 (formerly TTP399)'s landscape